SCHEMBL862901

SCHEMBL862901

CS(=O)(=O)Nc1cccc(S(=O)(=O)NC(=O)c2c(-c3ccc[nH]c3=O)c3cc(Cl)ccc3n2Cc2ccc(F)cc2F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C8 P10632 1/20 0.39
PPARG P37231 5/20 0.35
PTGDR2 Q9Y5Y4 4/20 0.34
CCR1 P32246 1/20 0.34
CCR2 P41597 1/20 0.34
MEN1 O00255 2/20 0.33
HPGD P15428 2/20 0.33
KMT2A Q03164 2/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33
PDE4A P27815 1/20 0.33
PDE7A Q13946 1/20 0.33
BRD4 O60885 1/20 0.33
TDP2 O95551 1/20 0.33
RIPK3 Q9Y572 1/20 0.33
LOXL2 Q9Y4K0 1/20 0.33
FBP1 P09467 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL862590 0.95 CYP2C8 (0.39) CYP2C8PPARGPTGDR2CCR1CCR2
SCHEMBL10258012 0.94 CYP2C8 (0.38) CYP2C8PPARGPTGDR2CCR1CCR2
SCHEMBL10255027 0.93 CYP2C8 (0.40) CYP2C8PPARGPTGDR2CCR1CCR2
SCHEMBL862574 0.93 CYP2C8 (0.41) CYP2C8PPARGPTGDR2MEN1HPGD
SCHEMBL10254940 0.93 CYP2C8 (0.38) CYP2C8PPARGPTGDR2MEN1KMT2A
SCHEMBL10255303 0.92 CYP2C8 (0.39) CYP2C8PPARGPTGDR2MEN1HPGD
SCHEMBL862564 0.92 CYP2C8 (0.36) CYP2C8PPARGPTGDR2MEN1KMT2A
SCHEMBL831326 0.92 CYP2C8 (0.40) CYP2C8PPARGPTGDR2CCR1CCR2
SCHEMBL862708 0.92 CYP2C8 (0.38) CYP2C8PPARGMEN1HPGDKMT2A
SCHEMBL862466 0.91 CYP2C8 (0.36) CYP2C8PPARGPTGDR2CCR1CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 CYP2C8 847/4885PPARG 4093/4885PTGDR2 1609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.